nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Carmustine—malignant glioma	0.0863	0.569	CbGbCtD
Ziprasidone—CYP3A4—Temozolomide—malignant glioma	0.0652	0.43	CbGbCtD
Ziprasidone—HTR1D—meninx—malignant glioma	0.023	0.073	CbGeAlD
Ziprasidone—HTR3A—fourth ventricle—malignant glioma	0.0224	0.0711	CbGeAlD
Ziprasidone—HTR1B—dura mater—malignant glioma	0.0219	0.0694	CbGeAlD
Ziprasidone—HTR1D—dura mater—malignant glioma	0.0212	0.0672	CbGeAlD
Ziprasidone—HTR2C—choroid plexus—malignant glioma	0.0178	0.0566	CbGeAlD
Ziprasidone—Teratogenicity—Carmustine—malignant glioma	0.0102	0.0354	CcSEcCtD
Ziprasidone—Pneumonia aspiration—Carmustine—malignant glioma	0.00977	0.034	CcSEcCtD
Ziprasidone—DRD3—telencephalic ventricle—malignant glioma	0.0094	0.0298	CbGeAlD
Ziprasidone—HTR2A—choroid plexus—malignant glioma	0.00895	0.0284	CbGeAlD
Ziprasidone—Tonic-clonic seizures—Carmustine—malignant glioma	0.00792	0.0276	CcSEcCtD
Ziprasidone—DRD1—telencephalic ventricle—malignant glioma	0.00673	0.0213	CbGeAlD
Ziprasidone—Cerebral infarction—Carmustine—malignant glioma	0.00655	0.0228	CcSEcCtD
Ziprasidone—Clozapine—CALY—malignant glioma	0.00614	1	CrCbGaD
Ziprasidone—Paresis—Temozolomide—malignant glioma	0.00565	0.0197	CcSEcCtD
Ziprasidone—HTR1B—telencephalic ventricle—malignant glioma	0.00545	0.0173	CbGeAlD
Ziprasidone—HTR1D—telencephalic ventricle—malignant glioma	0.00528	0.0167	CbGeAlD
Ziprasidone—HTR2C—telencephalic ventricle—malignant glioma	0.00523	0.0166	CbGeAlD
Ziprasidone—VIIth nerve paralysis—Carmustine—malignant glioma	0.0052	0.0181	CcSEcCtD
Ziprasidone—HTR7—pons—malignant glioma	0.00511	0.0162	CbGeAlD
Ziprasidone—Personality disorder—Carmustine—malignant glioma	0.00493	0.0172	CcSEcCtD
Ziprasidone—HTR2A—cerebellar cortex—malignant glioma	0.00451	0.0143	CbGeAlD
Ziprasidone—Grand mal convulsion—Carmustine—malignant glioma	0.00448	0.0156	CcSEcCtD
Ziprasidone—HTR1A—telencephalic ventricle—malignant glioma	0.0044	0.014	CbGeAlD
Ziprasidone—HTR7—telencephalic ventricle—malignant glioma	0.0042	0.0133	CbGeAlD
Ziprasidone—DRD2—telencephalic ventricle—malignant glioma	0.00397	0.0126	CbGeAlD
Ziprasidone—HTR2A—pons—malignant glioma	0.00319	0.0101	CbGeAlD
Ziprasidone—Tooth disorder—Temozolomide—malignant glioma	0.00318	0.0111	CcSEcCtD
Ziprasidone—HTR2A—vertebral column—malignant glioma	0.00316	0.01	CbGeAlD
Ziprasidone—Hypokinesia—Carmustine—malignant glioma	0.00316	0.011	CcSEcCtD
Ziprasidone—HTR1E—brainstem—malignant glioma	0.00312	0.00989	CbGeAlD
Ziprasidone—Myopathy—Temozolomide—malignant glioma	0.00294	0.0102	CcSEcCtD
Ziprasidone—Flat affect—Temozolomide—malignant glioma	0.00286	0.00995	CcSEcCtD
Ziprasidone—Scotoma—Carmustine—malignant glioma	0.00281	0.00978	CcSEcCtD
Ziprasidone—Menorrhagia—Temozolomide—malignant glioma	0.00279	0.00969	CcSEcCtD
Ziprasidone—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00279	0.00969	CcSEcCtD
Ziprasidone—HTR1E—telencephalon—malignant glioma	0.00277	0.00878	CbGeAlD
Ziprasidone—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00274	0.00953	CcSEcCtD
Ziprasidone—Scotoma—Temozolomide—malignant glioma	0.00272	0.00945	CcSEcCtD
Ziprasidone—HTR1B—blood vessel—malignant glioma	0.0027	0.00856	CbGeAlD
Ziprasidone—HTR2A—telencephalic ventricle—malignant glioma	0.00262	0.00831	CbGeAlD
Ziprasidone—Injection site pain—Carmustine—malignant glioma	0.00261	0.00909	CcSEcCtD
Ziprasidone—HTR1D—blood vessel—malignant glioma	0.00261	0.00829	CbGeAlD
Ziprasidone—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00251	0.00872	CcSEcCtD
Ziprasidone—Speech disorder—Carmustine—malignant glioma	0.00248	0.00863	CcSEcCtD
Ziprasidone—Accidental injury—Carmustine—malignant glioma	0.00241	0.00839	CcSEcCtD
Ziprasidone—Speech disorder—Temozolomide—malignant glioma	0.0024	0.00834	CcSEcCtD
Ziprasidone—Disturbance in attention—Temozolomide—malignant glioma	0.00238	0.00828	CcSEcCtD
Ziprasidone—Amenorrhoea—Temozolomide—malignant glioma	0.00235	0.00816	CcSEcCtD
Ziprasidone—Drug interaction—Carmustine—malignant glioma	0.0023	0.008	CcSEcCtD
Ziprasidone—HTR2A—pineal body—malignant glioma	0.00227	0.00721	CbGeAlD
Ziprasidone—Leukocytosis—Carmustine—malignant glioma	0.00227	0.0079	CcSEcCtD
Ziprasidone—HTR7—endothelium—malignant glioma	0.00226	0.00716	CbGeAlD
Ziprasidone—Gait disturbance—Carmustine—malignant glioma	0.00219	0.00761	CcSEcCtD
Ziprasidone—Hepatic enzyme increased—Temozolomide—malignant glioma	0.00218	0.00758	CcSEcCtD
Ziprasidone—Coordination abnormal—Carmustine—malignant glioma	0.00217	0.00756	CcSEcCtD
Ziprasidone—HTR6—telencephalon—malignant glioma	0.00217	0.00689	CbGeAlD
Ziprasidone—Pulmonary embolism—Carmustine—malignant glioma	0.00213	0.00742	CcSEcCtD
Ziprasidone—DRD5—telencephalon—malignant glioma	0.00211	0.00671	CbGeAlD
Ziprasidone—Gait disturbance—Temozolomide—malignant glioma	0.00211	0.00735	CcSEcCtD
Ziprasidone—Coordination abnormal—Temozolomide—malignant glioma	0.0021	0.00731	CcSEcCtD
Ziprasidone—HTR7—blood vessel—malignant glioma	0.00208	0.0066	CbGeAlD
Ziprasidone—Pulmonary embolism—Temozolomide—malignant glioma	0.00206	0.00717	CcSEcCtD
Ziprasidone—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00206	0.00717	CcSEcCtD
Ziprasidone—Urinary incontinence—Carmustine—malignant glioma	0.00206	0.00717	CcSEcCtD
Ziprasidone—H1F0—embryo—malignant glioma	0.00201	0.00638	CbGeAlD
Ziprasidone—Neuropathy—Carmustine—malignant glioma	0.002	0.00697	CcSEcCtD
Ziprasidone—Urinary incontinence—Temozolomide—malignant glioma	0.00199	0.00693	CcSEcCtD
Ziprasidone—Neuropathy—Temozolomide—malignant glioma	0.00194	0.00674	CcSEcCtD
Ziprasidone—Neoplasm—Carmustine—malignant glioma	0.00193	0.00671	CcSEcCtD
Ziprasidone—Gynaecomastia—Carmustine—malignant glioma	0.00191	0.00664	CcSEcCtD
Ziprasidone—Dry eye—Temozolomide—malignant glioma	0.0019	0.00663	CcSEcCtD
Ziprasidone—Neoplasm—Temozolomide—malignant glioma	0.00186	0.00649	CcSEcCtD
Ziprasidone—Abnormal vision—Carmustine—malignant glioma	0.00186	0.00647	CcSEcCtD
Ziprasidone—Sepsis—Carmustine—malignant glioma	0.00185	0.00644	CcSEcCtD
Ziprasidone—DRD1—brainstem—malignant glioma	0.00182	0.00577	CbGeAlD
Ziprasidone—Abnormal vision—Temozolomide—malignant glioma	0.0018	0.00626	CcSEcCtD
Ziprasidone—Phlebitis—Carmustine—malignant glioma	0.0018	0.00625	CcSEcCtD
Ziprasidone—Thrombophlebitis—Carmustine—malignant glioma	0.00179	0.00622	CcSEcCtD
Ziprasidone—Diabetes mellitus—Carmustine—malignant glioma	0.00178	0.0062	CcSEcCtD
Ziprasidone—H1F0—retina—malignant glioma	0.00178	0.00564	CbGeAlD
Ziprasidone—HTR3A—brainstem—malignant glioma	0.00176	0.00558	CbGeAlD
Ziprasidone—Ear pain—Temozolomide—malignant glioma	0.00175	0.0061	CcSEcCtD
Ziprasidone—Thrombophlebitis—Temozolomide—malignant glioma	0.00173	0.00602	CcSEcCtD
Ziprasidone—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00172	0.00599	CcSEcCtD
Ziprasidone—Injury—Carmustine—malignant glioma	0.00169	0.00586	CcSEcCtD
Ziprasidone—Amnesia—Carmustine—malignant glioma	0.00165	0.00574	CcSEcCtD
Ziprasidone—H1F0—telencephalon—malignant glioma	0.00164	0.00519	CbGeAlD
Ziprasidone—DRD1—telencephalon—malignant glioma	0.00162	0.00512	CbGeAlD
Ziprasidone—Amnesia—Temozolomide—malignant glioma	0.00159	0.00554	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Temozolomide—malignant glioma	0.00159	0.00552	CcSEcCtD
Ziprasidone—Thirst—Temozolomide—malignant glioma	0.00157	0.00547	CcSEcCtD
Ziprasidone—HTR1E—central nervous system—malignant glioma	0.00157	0.00499	CbGeAlD
Ziprasidone—HTR3A—telencephalon—malignant glioma	0.00156	0.00495	CbGeAlD
Ziprasidone—Hyponatraemia—Carmustine—malignant glioma	0.00156	0.00541	CcSEcCtD
Ziprasidone—Diplopia—Carmustine—malignant glioma	0.00155	0.00539	CcSEcCtD
Ziprasidone—Diplopia—Temozolomide—malignant glioma	0.0015	0.00521	CcSEcCtD
Ziprasidone—Face oedema—Carmustine—malignant glioma	0.0015	0.0052	CcSEcCtD
Ziprasidone—HTR1B—brainstem—malignant glioma	0.00147	0.00468	CbGeAlD
Ziprasidone—Ataxia—Carmustine—malignant glioma	0.00146	0.00507	CcSEcCtD
Ziprasidone—DRD4—brain—malignant glioma	0.00145	0.00459	CbGeAlD
Ziprasidone—Face oedema—Temozolomide—malignant glioma	0.00145	0.00503	CcSEcCtD
Ziprasidone—Liver function test abnormal—Carmustine—malignant glioma	0.00143	0.00497	CcSEcCtD
Ziprasidone—HTR1D—brainstem—malignant glioma	0.00143	0.00453	CbGeAlD
Ziprasidone—HTR2C—brainstem—malignant glioma	0.00141	0.00449	CbGeAlD
Ziprasidone—Hypokalaemia—Carmustine—malignant glioma	0.00141	0.0049	CcSEcCtD
Ziprasidone—Ataxia—Temozolomide—malignant glioma	0.00141	0.0049	CcSEcCtD
Ziprasidone—HTR2A—endothelium—malignant glioma	0.00141	0.00446	CbGeAlD
Ziprasidone—Dehydration—Temozolomide—malignant glioma	0.00139	0.00484	CcSEcCtD
Ziprasidone—CHRM4—central nervous system—malignant glioma	0.00138	0.00437	CbGeAlD
Ziprasidone—Hypokalaemia—Temozolomide—malignant glioma	0.00136	0.00474	CcSEcCtD
Ziprasidone—Breast disorder—Temozolomide—malignant glioma	0.00135	0.00471	CcSEcCtD
Ziprasidone—SLC6A4—brainstem—malignant glioma	0.00134	0.00425	CbGeAlD
Ziprasidone—Dysphagia—Carmustine—malignant glioma	0.00134	0.00466	CcSEcCtD
Ziprasidone—HTR1B—telencephalon—malignant glioma	0.00131	0.00415	CbGeAlD
Ziprasidone—CHRM2—telencephalon—malignant glioma	0.0013	0.00413	CbGeAlD
Ziprasidone—HTR2A—blood vessel—malignant glioma	0.0013	0.00412	CbGeAlD
Ziprasidone—Dysphagia—Temozolomide—malignant glioma	0.00129	0.0045	CcSEcCtD
Ziprasidone—H1F0—medulla oblongata—malignant glioma	0.00129	0.00408	CbGeAlD
Ziprasidone—DRD3—central nervous system—malignant glioma	0.00128	0.00407	CbGeAlD
Ziprasidone—HTR1D—telencephalon—malignant glioma	0.00127	0.00402	CbGeAlD
Ziprasidone—Sweating increased—Temozolomide—malignant glioma	0.00126	0.00438	CcSEcCtD
Ziprasidone—HTR2C—telencephalon—malignant glioma	0.00125	0.00398	CbGeAlD
Ziprasidone—HTR1E—brain—malignant glioma	0.00125	0.00396	CbGeAlD
Ziprasidone—HTR6—central nervous system—malignant glioma	0.00123	0.00391	CbGeAlD
Ziprasidone—Dysuria—Temozolomide—malignant glioma	0.00121	0.00421	CcSEcCtD
Ziprasidone—Hyperglycaemia—Carmustine—malignant glioma	0.00121	0.0042	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Temozolomide—malignant glioma	0.0012	0.00418	CcSEcCtD
Ziprasidone—DRD5—central nervous system—malignant glioma	0.0012	0.00381	CbGeAlD
Ziprasidone—Pneumonia—Carmustine—malignant glioma	0.0012	0.00418	CcSEcCtD
Ziprasidone—Erectile dysfunction—Temozolomide—malignant glioma	0.00119	0.00415	CcSEcCtD
Ziprasidone—HTR1A—brainstem—malignant glioma	0.00119	0.00378	CbGeAlD
Ziprasidone—SLC6A4—telencephalon—malignant glioma	0.00119	0.00377	CbGeAlD
Ziprasidone—CHRM1—telencephalon—malignant glioma	0.00119	0.00376	CbGeAlD
Ziprasidone—Photosensitivity reaction—Temozolomide—malignant glioma	0.00118	0.00411	CcSEcCtD
Ziprasidone—Weight increased—Temozolomide—malignant glioma	0.00118	0.0041	CcSEcCtD
Ziprasidone—H1F0—midbrain—malignant glioma	0.00117	0.00373	CbGeAlD
Ziprasidone—Renal failure—Carmustine—malignant glioma	0.00117	0.00408	CcSEcCtD
Ziprasidone—Weight decreased—Temozolomide—malignant glioma	0.00117	0.00407	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Carmustine—malignant glioma	0.00117	0.00407	CcSEcCtD
Ziprasidone—Hyperglycaemia—Temozolomide—malignant glioma	0.00117	0.00406	CcSEcCtD
Ziprasidone—Pneumonia—Temozolomide—malignant glioma	0.00116	0.00404	CcSEcCtD
Ziprasidone—DRD1—midbrain—malignant glioma	0.00116	0.00368	CbGeAlD
Ziprasidone—Infestation NOS—Temozolomide—malignant glioma	0.00115	0.00401	CcSEcCtD
Ziprasidone—Infestation—Temozolomide—malignant glioma	0.00115	0.00401	CcSEcCtD
Ziprasidone—H1F0—spinal cord—malignant glioma	0.00115	0.00364	CbGeAlD
Ziprasidone—HTR7—brainstem—malignant glioma	0.00114	0.00361	CbGeAlD
Ziprasidone—Neuropathy peripheral—Temozolomide—malignant glioma	0.00113	0.00393	CcSEcCtD
Ziprasidone—ADRA1A—brainstem—malignant glioma	0.0011	0.00348	CbGeAlD
Ziprasidone—CHRM4—brain—malignant glioma	0.0011	0.00347	CbGeAlD
Ziprasidone—CHRM5—central nervous system—malignant glioma	0.00108	0.00342	CbGeAlD
Ziprasidone—Haemoglobin—Carmustine—malignant glioma	0.00108	0.00375	CcSEcCtD
Ziprasidone—DRD2—brainstem—malignant glioma	0.00108	0.00341	CbGeAlD
Ziprasidone—Haemorrhage—Carmustine—malignant glioma	0.00107	0.00373	CcSEcCtD
Ziprasidone—Hypoaesthesia—Carmustine—malignant glioma	0.00107	0.00371	CcSEcCtD
Ziprasidone—CHRM3—telencephalon—malignant glioma	0.00106	0.00336	CbGeAlD
Ziprasidone—HTR1A—telencephalon—malignant glioma	0.00106	0.00335	CbGeAlD
Ziprasidone—Oedema peripheral—Carmustine—malignant glioma	0.00106	0.00367	CcSEcCtD
Ziprasidone—Connective tissue disorder—Carmustine—malignant glioma	0.00105	0.00366	CcSEcCtD
Ziprasidone—Haemoglobin—Temozolomide—malignant glioma	0.00104	0.00362	CcSEcCtD
Ziprasidone—DRD2—retina—malignant glioma	0.00104	0.00329	CbGeAlD
Ziprasidone—Haemorrhage—Temozolomide—malignant glioma	0.00104	0.0036	CcSEcCtD
Ziprasidone—Hepatitis—Temozolomide—malignant glioma	0.00104	0.0036	CcSEcCtD
Ziprasidone—Visual impairment—Carmustine—malignant glioma	0.00103	0.00359	CcSEcCtD
Ziprasidone—Hypoaesthesia—Temozolomide—malignant glioma	0.00103	0.00358	CcSEcCtD
Ziprasidone—Pharyngitis—Temozolomide—malignant glioma	0.00103	0.00358	CcSEcCtD
Ziprasidone—Urinary tract disorder—Temozolomide—malignant glioma	0.00102	0.00356	CcSEcCtD
Ziprasidone—Oedema peripheral—Temozolomide—malignant glioma	0.00102	0.00355	CcSEcCtD
Ziprasidone—DRD3—brain—malignant glioma	0.00102	0.00323	CbGeAlD
Ziprasidone—Connective tissue disorder—Temozolomide—malignant glioma	0.00102	0.00354	CcSEcCtD
Ziprasidone—Urethral disorder—Temozolomide—malignant glioma	0.00102	0.00353	CcSEcCtD
Ziprasidone—HTR7—telencephalon—malignant glioma	0.00101	0.0032	CbGeAlD
Ziprasidone—Eye disorder—Carmustine—malignant glioma	0.001	0.00348	CcSEcCtD
Ziprasidone—Visual impairment—Temozolomide—malignant glioma	0.000998	0.00347	CcSEcCtD
Ziprasidone—HTR2C—medulla oblongata—malignant glioma	0.000986	0.00313	CbGeAlD
Ziprasidone—ADRA1B—central nervous system—malignant glioma	0.000985	0.00312	CbGeAlD
Ziprasidone—HTR6—brain—malignant glioma	0.00098	0.00311	CbGeAlD
Ziprasidone—ADRA1A—telencephalon—malignant glioma	0.000974	0.00309	CbGeAlD
Ziprasidone—Eye disorder—Temozolomide—malignant glioma	0.000968	0.00337	CcSEcCtD
Ziprasidone—Tinnitus—Temozolomide—malignant glioma	0.000966	0.00336	CcSEcCtD
Ziprasidone—Cardiac disorder—Temozolomide—malignant glioma	0.000961	0.00334	CcSEcCtD
Ziprasidone—Arrhythmia—Carmustine—malignant glioma	0.000957	0.00333	CcSEcCtD
Ziprasidone—DRD2—telencephalon—malignant glioma	0.000954	0.00303	CbGeAlD
Ziprasidone—DRD5—brain—malignant glioma	0.000954	0.00303	CbGeAlD
Ziprasidone—Alopecia—Carmustine—malignant glioma	0.000947	0.00329	CcSEcCtD
Ziprasidone—KCNH2—telencephalon—malignant glioma	0.00094	0.00298	CbGeAlD
Ziprasidone—HTR1B—midbrain—malignant glioma	0.00094	0.00298	CbGeAlD
Ziprasidone—Angiopathy—Temozolomide—malignant glioma	0.00094	0.00327	CcSEcCtD
Ziprasidone—Mental disorder—Carmustine—malignant glioma	0.000939	0.00327	CcSEcCtD
Ziprasidone—Immune system disorder—Temozolomide—malignant glioma	0.000935	0.00325	CcSEcCtD
Ziprasidone—Mediastinal disorder—Temozolomide—malignant glioma	0.000933	0.00325	CcSEcCtD
Ziprasidone—Erythema—Carmustine—malignant glioma	0.000933	0.00325	CcSEcCtD
Ziprasidone—Malnutrition—Carmustine—malignant glioma	0.000933	0.00325	CcSEcCtD
Ziprasidone—H1F0—central nervous system—malignant glioma	0.00093	0.00295	CbGeAlD
Ziprasidone—Chills—Temozolomide—malignant glioma	0.000929	0.00323	CcSEcCtD
Ziprasidone—ADRA2C—telencephalon—malignant glioma	0.000928	0.00294	CbGeAlD
Ziprasidone—DRD1—central nervous system—malignant glioma	0.000918	0.00291	CbGeAlD
Ziprasidone—HTR1B—spinal cord—malignant glioma	0.000917	0.00291	CbGeAlD
Ziprasidone—Alopecia—Temozolomide—malignant glioma	0.000915	0.00318	CcSEcCtD
Ziprasidone—HTR1D—midbrain—malignant glioma	0.00091	0.00289	CbGeAlD
Ziprasidone—H1F0—cerebellum—malignant glioma	0.000909	0.00288	CbGeAlD
Ziprasidone—Mental disorder—Temozolomide—malignant glioma	0.000907	0.00316	CcSEcCtD
Ziprasidone—Back pain—Carmustine—malignant glioma	0.000902	0.00314	CcSEcCtD
Ziprasidone—Erythema—Temozolomide—malignant glioma	0.000902	0.00314	CcSEcCtD
Ziprasidone—Malnutrition—Temozolomide—malignant glioma	0.000902	0.00314	CcSEcCtD
Ziprasidone—HTR2C—midbrain—malignant glioma	0.000901	0.00286	CbGeAlD
Ziprasidone—HTR3A—central nervous system—malignant glioma	0.000887	0.00281	CbGeAlD
Ziprasidone—HTR2C—spinal cord—malignant glioma	0.000879	0.00279	CbGeAlD
Ziprasidone—Vision blurred—Carmustine—malignant glioma	0.000879	0.00306	CcSEcCtD
Ziprasidone—Tremor—Carmustine—malignant glioma	0.000874	0.00304	CcSEcCtD
Ziprasidone—Back pain—Temozolomide—malignant glioma	0.000872	0.00303	CcSEcCtD
Ziprasidone—Anaemia—Carmustine—malignant glioma	0.000862	0.003	CcSEcCtD
Ziprasidone—Agitation—Carmustine—malignant glioma	0.000857	0.00298	CcSEcCtD
Ziprasidone—CHRM5—brain—malignant glioma	0.000856	0.00271	CbGeAlD
Ziprasidone—SLC6A4—midbrain—malignant glioma	0.000854	0.00271	CbGeAlD
Ziprasidone—Vision blurred—Temozolomide—malignant glioma	0.00085	0.00296	CcSEcCtD
Ziprasidone—Tremor—Temozolomide—malignant glioma	0.000845	0.00294	CcSEcCtD
Ziprasidone—Leukopenia—Carmustine—malignant glioma	0.000835	0.0029	CcSEcCtD
Ziprasidone—SLC6A4—spinal cord—malignant glioma	0.000834	0.00264	CbGeAlD
Ziprasidone—Anaemia—Temozolomide—malignant glioma	0.000833	0.0029	CcSEcCtD
Ziprasidone—Agitation—Temozolomide—malignant glioma	0.000829	0.00288	CcSEcCtD
Ziprasidone—Angioedema—Temozolomide—malignant glioma	0.000824	0.00287	CcSEcCtD
Ziprasidone—Vertigo—Temozolomide—malignant glioma	0.00081	0.00282	CcSEcCtD
Ziprasidone—Leukopenia—Temozolomide—malignant glioma	0.000807	0.00281	CcSEcCtD
Ziprasidone—Hypertension—Carmustine—malignant glioma	0.000805	0.0028	CcSEcCtD
Ziprasidone—Palpitations—Temozolomide—malignant glioma	0.000797	0.00277	CcSEcCtD
Ziprasidone—Chest pain—Carmustine—malignant glioma	0.000794	0.00276	CcSEcCtD
Ziprasidone—Myalgia—Carmustine—malignant glioma	0.000794	0.00276	CcSEcCtD
Ziprasidone—HTR7—medulla oblongata—malignant glioma	0.000793	0.00252	CbGeAlD
Ziprasidone—Anxiety—Carmustine—malignant glioma	0.000792	0.00275	CcSEcCtD
Ziprasidone—Cough—Temozolomide—malignant glioma	0.000787	0.00274	CcSEcCtD
Ziprasidone—ADRA1B—brain—malignant glioma	0.000782	0.00248	CbGeAlD
Ziprasidone—Hypertension—Temozolomide—malignant glioma	0.000778	0.00271	CcSEcCtD
Ziprasidone—HTR2A—embryo—malignant glioma	0.000774	0.00246	CbGeAlD
Ziprasidone—Confusional state—Carmustine—malignant glioma	0.000768	0.00267	CcSEcCtD
Ziprasidone—Myalgia—Temozolomide—malignant glioma	0.000768	0.00267	CcSEcCtD
Ziprasidone—Arthralgia—Temozolomide—malignant glioma	0.000768	0.00267	CcSEcCtD
Ziprasidone—Anxiety—Temozolomide—malignant glioma	0.000765	0.00266	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000762	0.00265	CcSEcCtD
Ziprasidone—HTR1A—midbrain—malignant glioma	0.000759	0.00241	CbGeAlD
Ziprasidone—Infection—Carmustine—malignant glioma	0.000756	0.00263	CcSEcCtD
Ziprasidone—HRH1—telencephalon—malignant glioma	0.000754	0.00239	CbGeAlD
Ziprasidone—Dry mouth—Temozolomide—malignant glioma	0.000751	0.00261	CcSEcCtD
Ziprasidone—Thrombocytopenia—Carmustine—malignant glioma	0.000745	0.00259	CcSEcCtD
Ziprasidone—HTR1B—central nervous system—malignant glioma	0.000744	0.00236	CbGeAlD
Ziprasidone—Tachycardia—Carmustine—malignant glioma	0.000743	0.00258	CcSEcCtD
Ziprasidone—Confusional state—Temozolomide—malignant glioma	0.000742	0.00258	CcSEcCtD
Ziprasidone—ADRA2A—telencephalon—malignant glioma	0.00074	0.00235	CbGeAlD
Ziprasidone—HTR1A—spinal cord—malignant glioma	0.00074	0.00235	CbGeAlD
Ziprasidone—CHRM2—central nervous system—malignant glioma	0.00074	0.00235	CbGeAlD
Ziprasidone—KCNH2—medulla oblongata—malignant glioma	0.000739	0.00234	CbGeAlD
Ziprasidone—H1F0—brain—malignant glioma	0.000738	0.00234	CbGeAlD
Ziprasidone—Infection—Temozolomide—malignant glioma	0.000731	0.00254	CcSEcCtD
Ziprasidone—ADRA2C—medulla oblongata—malignant glioma	0.000729	0.00231	CbGeAlD
Ziprasidone—DRD1—brain—malignant glioma	0.000729	0.00231	CbGeAlD
Ziprasidone—Anorexia—Carmustine—malignant glioma	0.000726	0.00252	CcSEcCtD
Ziprasidone—HTR7—midbrain—malignant glioma	0.000725	0.0023	CbGeAlD
Ziprasidone—Nervous system disorder—Temozolomide—malignant glioma	0.000722	0.00251	CcSEcCtD
Ziprasidone—Thrombocytopenia—Temozolomide—malignant glioma	0.00072	0.00251	CcSEcCtD
Ziprasidone—HTR1D—central nervous system—malignant glioma	0.00072	0.00228	CbGeAlD
Ziprasidone—Skin disorder—Temozolomide—malignant glioma	0.000715	0.00249	CcSEcCtD
Ziprasidone—HTR2C—central nervous system—malignant glioma	0.000713	0.00226	CbGeAlD
Ziprasidone—Hypotension—Carmustine—malignant glioma	0.000711	0.00247	CcSEcCtD
Ziprasidone—Hyperhidrosis—Temozolomide—malignant glioma	0.000711	0.00247	CcSEcCtD
Ziprasidone—HTR2A—brainstem—malignant glioma	0.000709	0.00225	CbGeAlD
Ziprasidone—HTR7—spinal cord—malignant glioma	0.000707	0.00224	CbGeAlD
Ziprasidone—HTR3A—brain—malignant glioma	0.000704	0.00223	CbGeAlD
Ziprasidone—Anorexia—Temozolomide—malignant glioma	0.000701	0.00244	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000694	0.00241	CcSEcCtD
Ziprasidone—Insomnia—Carmustine—malignant glioma	0.000689	0.0024	CcSEcCtD
Ziprasidone—DRD2—midbrain—malignant glioma	0.000685	0.00217	CbGeAlD
Ziprasidone—HTR2A—retina—malignant glioma	0.000684	0.00217	CbGeAlD
Ziprasidone—Paraesthesia—Carmustine—malignant glioma	0.000684	0.00238	CcSEcCtD
Ziprasidone—Dyspnoea—Carmustine—malignant glioma	0.000679	0.00236	CcSEcCtD
Ziprasidone—Somnolence—Carmustine—malignant glioma	0.000677	0.00235	CcSEcCtD
Ziprasidone—SLC6A4—central nervous system—malignant glioma	0.000676	0.00214	CbGeAlD
Ziprasidone—KCNH2—midbrain—malignant glioma	0.000675	0.00214	CbGeAlD
Ziprasidone—CHRM1—central nervous system—malignant glioma	0.000674	0.00214	CbGeAlD
Ziprasidone—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00067	0.00233	CcSEcCtD
Ziprasidone—ADRA2C—midbrain—malignant glioma	0.000666	0.00211	CbGeAlD
Ziprasidone—Insomnia—Temozolomide—malignant glioma	0.000665	0.00231	CcSEcCtD
Ziprasidone—Decreased appetite—Carmustine—malignant glioma	0.000662	0.0023	CcSEcCtD
Ziprasidone—Paraesthesia—Temozolomide—malignant glioma	0.000661	0.0023	CcSEcCtD
Ziprasidone—KCNH2—spinal cord—malignant glioma	0.000659	0.00209	CbGeAlD
Ziprasidone—Gastrointestinal disorder—Carmustine—malignant glioma	0.000657	0.00229	CcSEcCtD
Ziprasidone—Dyspnoea—Temozolomide—malignant glioma	0.000656	0.00228	CcSEcCtD
Ziprasidone—Somnolence—Temozolomide—malignant glioma	0.000654	0.00228	CcSEcCtD
Ziprasidone—Constipation—Carmustine—malignant glioma	0.000651	0.00226	CcSEcCtD
Ziprasidone—ADRA2C—spinal cord—malignant glioma	0.00065	0.00206	CbGeAlD
Ziprasidone—Dyspepsia—Temozolomide—malignant glioma	0.000648	0.00225	CcSEcCtD
Ziprasidone—CYP2D6—brainstem—malignant glioma	0.000646	0.00205	CbGeAlD
Ziprasidone—Decreased appetite—Temozolomide—malignant glioma	0.00064	0.00222	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000635	0.00221	CcSEcCtD
Ziprasidone—Fatigue—Temozolomide—malignant glioma	0.000634	0.00221	CcSEcCtD
Ziprasidone—HTR2A—telencephalon—malignant glioma	0.00063	0.002	CbGeAlD
Ziprasidone—Constipation—Temozolomide—malignant glioma	0.000629	0.00219	CcSEcCtD
Ziprasidone—Feeling abnormal—Carmustine—malignant glioma	0.000627	0.00218	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Carmustine—malignant glioma	0.000623	0.00217	CcSEcCtD
Ziprasidone—Feeling abnormal—Temozolomide—malignant glioma	0.000606	0.00211	CcSEcCtD
Ziprasidone—CHRM3—central nervous system—malignant glioma	0.000603	0.00191	CbGeAlD
Ziprasidone—Abdominal pain—Carmustine—malignant glioma	0.000602	0.00209	CcSEcCtD
Ziprasidone—Body temperature increased—Carmustine—malignant glioma	0.000602	0.00209	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Temozolomide—malignant glioma	0.000602	0.00209	CcSEcCtD
Ziprasidone—HTR1A—central nervous system—malignant glioma	0.0006	0.0019	CbGeAlD
Ziprasidone—HTR1B—brain—malignant glioma	0.000591	0.00187	CbGeAlD
Ziprasidone—CHRM2—brain—malignant glioma	0.000588	0.00186	CbGeAlD
Ziprasidone—HTR1A—cerebellum—malignant glioma	0.000587	0.00186	CbGeAlD
Ziprasidone—Urticaria—Temozolomide—malignant glioma	0.000585	0.00203	CcSEcCtD
Ziprasidone—ADRA2A—medulla oblongata—malignant glioma	0.000582	0.00185	CbGeAlD
Ziprasidone—Body temperature increased—Temozolomide—malignant glioma	0.000582	0.00202	CcSEcCtD
Ziprasidone—Abdominal pain—Temozolomide—malignant glioma	0.000582	0.00202	CcSEcCtD
Ziprasidone—HTR7—central nervous system—malignant glioma	0.000574	0.00182	CbGeAlD
Ziprasidone—CYP2D6—telencephalon—malignant glioma	0.000573	0.00182	CbGeAlD
Ziprasidone—HTR1D—brain—malignant glioma	0.000572	0.00181	CbGeAlD
Ziprasidone—HTR2C—brain—malignant glioma	0.000566	0.0018	CbGeAlD
Ziprasidone—Hypersensitivity—Carmustine—malignant glioma	0.000561	0.00195	CcSEcCtD
Ziprasidone—HTR7—cerebellum—malignant glioma	0.000561	0.00178	CbGeAlD
Ziprasidone—ADRA1A—central nervous system—malignant glioma	0.000553	0.00176	CbGeAlD
Ziprasidone—Asthenia—Carmustine—malignant glioma	0.000546	0.0019	CcSEcCtD
Ziprasidone—DRD2—central nervous system—malignant glioma	0.000542	0.00172	CbGeAlD
Ziprasidone—Hypersensitivity—Temozolomide—malignant glioma	0.000542	0.00189	CcSEcCtD
Ziprasidone—ADRA1A—cerebellum—malignant glioma	0.000541	0.00172	CbGeAlD
Ziprasidone—SLC6A4—brain—malignant glioma	0.000537	0.0017	CbGeAlD
Ziprasidone—CHRM1—brain—malignant glioma	0.000535	0.0017	CbGeAlD
Ziprasidone—KCNH2—central nervous system—malignant glioma	0.000535	0.0017	CbGeAlD
Ziprasidone—ADRA2A—midbrain—malignant glioma	0.000532	0.00169	CbGeAlD
Ziprasidone—DRD2—cerebellum—malignant glioma	0.00053	0.00168	CbGeAlD
Ziprasidone—Asthenia—Temozolomide—malignant glioma	0.000528	0.00184	CcSEcCtD
Ziprasidone—ADRA2C—central nervous system—malignant glioma	0.000527	0.00167	CbGeAlD
Ziprasidone—KCNH2—cerebellum—malignant glioma	0.000522	0.00166	CbGeAlD
Ziprasidone—Diarrhoea—Carmustine—malignant glioma	0.000521	0.00181	CcSEcCtD
Ziprasidone—ADRA2A—spinal cord—malignant glioma	0.000519	0.00165	CbGeAlD
Ziprasidone—ADRA2C—cerebellum—malignant glioma	0.000515	0.00163	CbGeAlD
Ziprasidone—Dizziness—Carmustine—malignant glioma	0.000503	0.00175	CcSEcCtD
Ziprasidone—Diarrhoea—Temozolomide—malignant glioma	0.000503	0.00175	CcSEcCtD
Ziprasidone—HTR2A—medulla oblongata—malignant glioma	0.000495	0.00157	CbGeAlD
Ziprasidone—Dizziness—Temozolomide—malignant glioma	0.000487	0.00169	CcSEcCtD
Ziprasidone—Vomiting—Carmustine—malignant glioma	0.000484	0.00168	CcSEcCtD
Ziprasidone—Rash—Carmustine—malignant glioma	0.00048	0.00167	CcSEcCtD
Ziprasidone—Dermatitis—Carmustine—malignant glioma	0.00048	0.00167	CcSEcCtD
Ziprasidone—CHRM3—brain—malignant glioma	0.000479	0.00152	CbGeAlD
Ziprasidone—Headache—Carmustine—malignant glioma	0.000477	0.00166	CcSEcCtD
Ziprasidone—HTR1A—brain—malignant glioma	0.000477	0.00151	CbGeAlD
Ziprasidone—Vomiting—Temozolomide—malignant glioma	0.000468	0.00163	CcSEcCtD
Ziprasidone—Rash—Temozolomide—malignant glioma	0.000464	0.00161	CcSEcCtD
Ziprasidone—Dermatitis—Temozolomide—malignant glioma	0.000464	0.00161	CcSEcCtD
Ziprasidone—Headache—Temozolomide—malignant glioma	0.000461	0.0016	CcSEcCtD
Ziprasidone—HTR7—brain—malignant glioma	0.000456	0.00144	CbGeAlD
Ziprasidone—Nausea—Carmustine—malignant glioma	0.000452	0.00157	CcSEcCtD
Ziprasidone—HTR2A—midbrain—malignant glioma	0.000452	0.00143	CbGeAlD
Ziprasidone—HTR2A—spinal cord—malignant glioma	0.000441	0.0014	CbGeAlD
Ziprasidone—ADRA1A—brain—malignant glioma	0.000439	0.00139	CbGeAlD
Ziprasidone—Nausea—Temozolomide—malignant glioma	0.000437	0.00152	CcSEcCtD
Ziprasidone—DRD2—brain—malignant glioma	0.000431	0.00137	CbGeAlD
Ziprasidone—HRH1—central nervous system—malignant glioma	0.000428	0.00136	CbGeAlD
Ziprasidone—KCNH2—brain—malignant glioma	0.000424	0.00135	CbGeAlD
Ziprasidone—ADRA2A—central nervous system—malignant glioma	0.000421	0.00133	CbGeAlD
Ziprasidone—ADRA2C—brain—malignant glioma	0.000419	0.00133	CbGeAlD
Ziprasidone—ADRA2A—cerebellum—malignant glioma	0.000411	0.0013	CbGeAlD
Ziprasidone—HTR2A—central nervous system—malignant glioma	0.000358	0.00113	CbGeAlD
Ziprasidone—HTR2A—cerebellum—malignant glioma	0.00035	0.00111	CbGeAlD
Ziprasidone—HRH1—brain—malignant glioma	0.00034	0.00108	CbGeAlD
Ziprasidone—ADRA2A—brain—malignant glioma	0.000334	0.00106	CbGeAlD
Ziprasidone—CYP3A4—central nervous system—malignant glioma	0.000331	0.00105	CbGeAlD
Ziprasidone—CYP2D6—central nervous system—malignant glioma	0.000326	0.00103	CbGeAlD
Ziprasidone—CYP2D6—cerebellum—malignant glioma	0.000319	0.00101	CbGeAlD
Ziprasidone—HTR2A—brain—malignant glioma	0.000284	0.000901	CbGeAlD
Ziprasidone—CYP2D6—brain—malignant glioma	0.000259	0.000821	CbGeAlD
Ziprasidone—CHRM4—Signaling Pathways—KRAS—malignant glioma	8.15e-06	3.4e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCL8—malignant glioma	8.14e-06	3.4e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—AKT1—malignant glioma	8.13e-06	3.39e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MMP9—malignant glioma	8.11e-06	3.39e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—AKT1—malignant glioma	8.09e-06	3.38e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PTEN—malignant glioma	8.06e-06	3.37e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MYC—malignant glioma	8.05e-06	3.36e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCL8—malignant glioma	8.01e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCL8—malignant glioma	7.99e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MMP9—malignant glioma	7.98e-06	3.33e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCL8—malignant glioma	7.96e-06	3.32e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MYC—malignant glioma	7.95e-06	3.32e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—PIK3CA—malignant glioma	7.94e-06	3.32e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCL8—malignant glioma	7.94e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PTEN—malignant glioma	7.94e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—PIK3CA—malignant glioma	7.93e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	7.88e-06	3.29e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—malignant glioma	7.88e-06	3.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—AKT1—malignant glioma	7.87e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCL8—malignant glioma	7.86e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—AKT1—malignant glioma	7.86e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	7.84e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTEN—malignant glioma	7.83e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	7.82e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KRAS—malignant glioma	7.81e-06	3.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—malignant glioma	7.8e-06	3.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MDM2—malignant glioma	7.79e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CASP3—malignant glioma	7.79e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL2—malignant glioma	7.78e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—malignant glioma	7.77e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RAF1—malignant glioma	7.76e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	7.74e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	7.73e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—STAT3—malignant glioma	7.72e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—AKT1—malignant glioma	7.72e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—PIK3CA—malignant glioma	7.72e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CG—malignant glioma	7.71e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—AKT1—malignant glioma	7.69e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—malignant glioma	7.68e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	7.68e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—malignant glioma	7.67e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—AKT1—malignant glioma	7.67e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CASP3—malignant glioma	7.66e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL2—malignant glioma	7.65e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CASP3—malignant glioma	7.65e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL2—malignant glioma	7.64e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—malignant glioma	7.62e-06	3.18e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CASP3—malignant glioma	7.62e-06	3.18e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL2—malignant glioma	7.61e-06	3.18e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CASP3—malignant glioma	7.6e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—PIK3CA—malignant glioma	7.59e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—AKT1—malignant glioma	7.59e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL2—malignant glioma	7.59e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	7.58e-06	3.16e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	7.57e-06	3.16e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—malignant glioma	7.53e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CASP3—malignant glioma	7.52e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL2—malignant glioma	7.51e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CASP3—malignant glioma	7.5e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL2—malignant glioma	7.49e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—PIK3CA—malignant glioma	7.49e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—malignant glioma	7.49e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—malignant glioma	7.47e-06	3.12e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—STAT3—malignant glioma	7.45e-06	3.11e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KRAS—malignant glioma	7.44e-06	3.11e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PPARG—malignant glioma	7.44e-06	3.11e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—STAT3—malignant glioma	7.41e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTP1—malignant glioma	7.39e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—malignant glioma	7.36e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—malignant glioma	7.35e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KRAS—malignant glioma	7.34e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PTEN—malignant glioma	7.32e-06	3.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	7.28e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—malignant glioma	7.28e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—malignant glioma	7.25e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—malignant glioma	7.24e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—malignant glioma	7.23e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STAT3—malignant glioma	7.21e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—malignant glioma	7.2e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTEN—malignant glioma	7.2e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CAT—malignant glioma	7.19e-06	3e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTEN—malignant glioma	7.18e-06	3e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—malignant glioma	7.18e-06	3e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTEN—malignant glioma	7.18e-06	3e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PIK3CA—malignant glioma	7.17e-06	3e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MYC—malignant glioma	7.17e-06	3e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CAV1—malignant glioma	7.17e-06	2.99e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	7.17e-06	2.99e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTEN—malignant glioma	7.16e-06	2.99e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AKT1—malignant glioma	7.14e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—malignant glioma	7.14e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—malignant glioma	7.11e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—malignant glioma	7.1e-06	2.96e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—malignant glioma	7.09e-06	2.96e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—malignant glioma	7.07e-06	2.95e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—malignant glioma	7.05e-06	2.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	7.04e-06	2.94e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—malignant glioma	7.02e-06	2.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—malignant glioma	7.02e-06	2.93e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—malignant glioma	7.01e-06	2.93e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PIK3CA—malignant glioma	7.01e-06	2.92e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—malignant glioma	6.99e-06	2.92e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP3—malignant glioma	6.97e-06	2.91e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—malignant glioma	6.96e-06	2.91e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—malignant glioma	6.96e-06	2.91e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—malignant glioma	6.94e-06	2.9e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—malignant glioma	6.93e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—malignant glioma	6.9e-06	2.88e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—malignant glioma	6.89e-06	2.88e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	6.88e-06	2.87e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.85e-06	2.86e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PIK3CA—malignant glioma	6.84e-06	2.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PIK3CA—malignant glioma	6.8e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—NCOR1—malignant glioma	6.79e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CD—malignant glioma	6.78e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—malignant glioma	6.77e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PIK3CA—malignant glioma	6.75e-06	2.82e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—malignant glioma	6.74e-06	2.81e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—malignant glioma	6.7e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—malignant glioma	6.63e-06	2.77e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—malignant glioma	6.61e-06	2.76e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—malignant glioma	6.61e-06	2.76e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—malignant glioma	6.6e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—malignant glioma	6.59e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—malignant glioma	6.55e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—malignant glioma	6.55e-06	2.73e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—malignant glioma	6.54e-06	2.73e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CG—malignant glioma	6.53e-06	2.73e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—malignant glioma	6.53e-06	2.72e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—malignant glioma	6.5e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—malignant glioma	6.49e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—malignant glioma	6.49e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—malignant glioma	6.48e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—malignant glioma	6.47e-06	2.7e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—malignant glioma	6.45e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—malignant glioma	6.45e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—malignant glioma	6.44e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—malignant glioma	6.44e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—malignant glioma	6.42e-06	2.68e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—malignant glioma	6.4e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—malignant glioma	6.4e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	6.39e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—malignant glioma	6.38e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—malignant glioma	6.38e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	6.37e-06	2.66e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—malignant glioma	6.37e-06	2.66e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—malignant glioma	6.32e-06	2.64e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—malignant glioma	6.3e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—malignant glioma	6.3e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARG—malignant glioma	6.3e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—malignant glioma	6.2e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—malignant glioma	6.19e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—malignant glioma	6.12e-06	2.56e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—malignant glioma	6.09e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PIK3CA—malignant glioma	6.09e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—malignant glioma	6.08e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PIK3CA—malignant glioma	6.02e-06	2.51e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—malignant glioma	5.98e-06	2.5e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—malignant glioma	5.97e-06	2.49e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—malignant glioma	5.95e-06	2.48e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—malignant glioma	5.95e-06	2.48e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—malignant glioma	5.93e-06	2.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	5.92e-06	2.47e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CB—malignant glioma	5.91e-06	2.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—malignant glioma	5.89e-06	2.46e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	5.88e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—malignant glioma	5.87e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—malignant glioma	5.86e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—malignant glioma	5.86e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—malignant glioma	5.86e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—malignant glioma	5.85e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—malignant glioma	5.85e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	5.85e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—malignant glioma	5.84e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—malignant glioma	5.82e-06	2.43e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—malignant glioma	5.8e-06	2.42e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—malignant glioma	5.75e-06	2.4e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CD—malignant glioma	5.74e-06	2.4e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—malignant glioma	5.73e-06	2.39e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—malignant glioma	5.72e-06	2.39e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PIK3CA—malignant glioma	5.69e-06	2.38e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—malignant glioma	5.69e-06	2.37e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—malignant glioma	5.66e-06	2.36e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—malignant glioma	5.62e-06	2.35e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	5.6e-06	2.34e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—malignant glioma	5.59e-06	2.33e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—malignant glioma	5.56e-06	2.32e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CAV1—malignant glioma	5.53e-06	2.31e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—malignant glioma	5.53e-06	2.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PIK3CA—malignant glioma	5.53e-06	2.31e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—malignant glioma	5.52e-06	2.3e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—malignant glioma	5.51e-06	2.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—malignant glioma	5.5e-06	2.3e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—malignant glioma	5.5e-06	2.3e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—malignant glioma	5.48e-06	2.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—malignant glioma	5.44e-06	2.27e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—malignant glioma	5.43e-06	2.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—malignant glioma	5.42e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—malignant glioma	5.41e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—malignant glioma	5.32e-06	2.22e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PIK3CA—malignant glioma	5.16e-06	2.16e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—malignant glioma	5.1e-06	2.13e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	5.08e-06	2.12e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PIK3CA—malignant glioma	5.07e-06	2.12e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PIK3CA—malignant glioma	5.06e-06	2.11e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PIK3CA—malignant glioma	5.05e-06	2.11e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CG—malignant glioma	5.04e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PIK3CA—malignant glioma	5.04e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—malignant glioma	5.03e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CB—malignant glioma	5e-06	2.09e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—malignant glioma	4.99e-06	2.08e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PIK3CA—malignant glioma	4.99e-06	2.08e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—malignant glioma	4.98e-06	2.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	4.97e-06	2.08e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—malignant glioma	4.96e-06	2.07e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—malignant glioma	4.92e-06	2.05e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—malignant glioma	4.91e-06	2.05e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—malignant glioma	4.9e-06	2.05e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—malignant glioma	4.89e-06	2.04e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—malignant glioma	4.87e-06	2.03e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARG—malignant glioma	4.86e-06	2.03e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—malignant glioma	4.82e-06	2.01e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—malignant glioma	4.81e-06	2.01e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—malignant glioma	4.8e-06	2.01e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—malignant glioma	4.78e-06	1.99e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—malignant glioma	4.65e-06	1.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	4.62e-06	1.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—malignant glioma	4.57e-06	1.91e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—malignant glioma	4.51e-06	1.88e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—malignant glioma	4.47e-06	1.87e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CD—malignant glioma	4.43e-06	1.85e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—malignant glioma	4.32e-06	1.81e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—malignant glioma	4.22e-06	1.76e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—malignant glioma	4.15e-06	1.73e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—malignant glioma	4.14e-06	1.73e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—malignant glioma	4.14e-06	1.73e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—malignant glioma	4.13e-06	1.72e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—malignant glioma	4.11e-06	1.72e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—malignant glioma	4.07e-06	1.7e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—malignant glioma	4.06e-06	1.7e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CB—malignant glioma	3.86e-06	1.61e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—malignant glioma	3.83e-06	1.6e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—malignant glioma	3.77e-06	1.58e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CA—malignant glioma	3.6e-06	1.5e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—malignant glioma	3.34e-06	1.39e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CA—malignant glioma	3.05e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—malignant glioma	2.94e-06	1.23e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—malignant glioma	2.49e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CA—malignant glioma	2.35e-06	9.83e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—malignant glioma	1.92e-06	8.03e-06	CbGpPWpGaD
